All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (liver ) PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), atezolizumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
IMpower-130 (all population), 2019 0.80 [0.65; 0.99]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06]
IMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.76 [0.63; 0.92]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02]
0.80 [0.74 ; 0.86 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 9 0% 5,470 moderate serious deaths (OS) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
0.76 [0.53 ; 1.08 ] IMpower-110 (TC3 or IC3), 2020 1 0% 205 NA not evaluable PFS (extension)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
0.67 [0.59 ; 0.77 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020 3 0% 1,087 moderate not evaluable progression or deaths (PFS)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
IMpower-130 (all population), 2019 0.65 [0.54; 0.78]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68]
IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.61 [0.52; 0.72]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06]
0.67 [0.61 ; 0.75 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (all population), 2019, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 10 61% 5,750 moderate low DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04]
2.27 [1.44 ; 3.57 ] IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020 2 0% 601 moderate not evaluable objective responses (ORR)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92]
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19]
IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.95 [1.47; 2.58]
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35]
1.45 [1.15 ; 1.82 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018, IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 9 73% 5,001 moderate not evaluable objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
1.68 [0.94 ; 3.01 ] IMpower-110 (TC3 or IC3), 2020 1 0% 205 NA not evaluable AE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
IMpower-130 (all population), 2019 2.05 [0.29; 14.63]
IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.49 [0.15; 1.65]
1.07 [0.37 ; 3.10 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 66% 2,709 moderate not evaluable AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
IMpower-130 (all population), 2019 1.72 [1.19; 2.47]
IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.14 [0.86; 1.52]
1.01 [0.55 ; 1.86 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 93% 2,709 moderate not evaluable AE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
IMpower-130 (all population), 2019 0.94 [0.47; 1.87]
IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.10 [0.60; 2.03]
1.28 [0.78 ; 2.11 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 52% 2,709 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
IMpower-130 (all population), 2019 1.27 [0.88; 1.85]
IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.46 [1.07; 1.99]
1.12 [0.62 ; 2.02 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 89% 2,709 moderate not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
IMpower-130 (all population), 2019 1.69 [1.22; 2.32]
IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.40 [1.05; 1.87]
1.53 [1.11 ; 2.11 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 75% 2,709 moderate not evaluable STRAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
IMpower-130 (all population), 2019 2.09 [1.35; 3.24]
IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.43 [1.02; 2.00]
1.38 [0.77 ; 2.47 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 86% 2,709 moderate not evaluable TRAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
IMpower-130 (all population), 2019 2.00 [1.01; 3.95]
IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.81 [0.43; 1.53]
0.92 [0.33 ; 2.60 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 92% 2,709 moderate not evaluable TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
IMpower-130 (all population), 2019 1.79 [1.28; 2.50]
IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.38 [1.04; 1.83]
0.93 [0.39 ; 2.23 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 96% 2,709 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
1.37 [0.68 ; 2.78 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4 0% 2,709 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.06; 16.09]
1.32 [0.15 ; 11.35 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
0.79 [0.08 ; 7.60 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.62 [1.11; 2.36]
IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.05 [0.58; 1.89]
1.27 [0.96 ; 1.68 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 25% 2,160 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.75 [0.17; 3.37]
0.78 [0.19 ; 3.17 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.45 [0.15; 1.30]
0.74 [0.39 ; 1.40 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.53 [0.49; 13.10]
3.39 [0.92 ; 12.50 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,004 moderate not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
0.77 [0.10 ; 5.99 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.86 [0.25; 2.95]
IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
1.96 [0.71 ; 5.43 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 29% 2,160 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 6.05 [0.30; 121.16]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.02; 50.65]
3.12 [0.29 ; 33.74 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.03 [0.49; 2.14]
IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 5.64 [1.24; 25.63]
1.65 [0.72 ; 3.78 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 49% 2,160 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Epistaxis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
8.09 [0.43 ; 153.59 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.02 [0.53; 1.96]
IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.31 [0.57; 3.03]
1.27 [0.81 ; 1.99 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.66 [1.10; 6.46]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.48 [0.85; 2.57]
1.78 [1.04 ; 3.05 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 18% 1,455 moderate not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 8.09 [0.43; 153.59]
5.48 [1.30 ; 23.18 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 1% 2,004 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.00 [0.57; 1.78]
1.00 [0.57 ; 1.78 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
1.62 [0.21 ; 12.58 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,004 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.18 [0.30 ; 15.78 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,004 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
0.96 [0.06 ; 15.37 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020 2 0% 1,217 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.46 [0.72; 2.93]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.77 [0.51; 6.09]
1.53 [0.83 ; 2.81 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.18; 22.26]
1.66 [0.21 ; 12.91 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
1.49 [0.11 ; 19.42 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.61 [0.52; 5.00]
IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.91 [0.80; 4.57]
2.00 [1.06 ; 3.77 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
1.49 [0.11 ; 19.42 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.22 [0.86; 1.72]
IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.27 [0.83; 1.94]
1.12 [0.90 ; 1.39 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.03 [0.18; 89.56]
2.93 [0.30 ; 28.98 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Paraesthesia TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.50 [0.02; 14.97]
0.50 [0.02 ; 14.97 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.01 [0.37; 11.06]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.23 [0.50; 3.01]
1.37 [0.62 ; 3.02 ] IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2 0% 1,455 moderate not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 4.04 [0.45; 36.31]
4.04 [0.45 ; 36.31 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3.04 [0.61; 15.15]
2.31 [0.84 ; 6.37 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,004 moderate not evaluable Rash TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 10.14 [0.55; 186.27]
2.28 [0.63 ; 8.28 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,004 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 2.01 [0.07; 60.02]
2.01 [0.07 ; 60.02 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 4.04 [0.45; 36.32]
4.04 [0.45 ; 36.32 ] IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1 0% 787 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.52 [0.83; 2.79]
IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 0.94 [0.47; 1.89]
1.21 [0.85 ; 1.71 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.48 [0.40; 5.52]
IMpower-131 (ACnP), 2020 3.02 [0.31; 29.16]
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 1.21 [0.37; 3.99]
1.48 [0.65 ; 3.36 ] IMpower-130 (all population), 2019, IMpower-131 (ACnP), 2020, IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 3 0% 2,160 moderate not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.23 [0.24; 6.38]
1.23 [0.24 ; 6.38 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Agranulocytosis (AE grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Alopecia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
IMpower-130 (all population), 2019 1.47 [1.03; 2.11]
0.35 [0.02 ; 6.18 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 97% 1,254 moderate not evaluable Arthralgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 7.97 [0.46; 139.30]
7.97 [0.46 ; 139.30 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
0.88 [0.21 ; 3.64 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 55% 1,254 moderate not evaluable Back pain AE (grade 3-4)detailed results IMpower-130 (all population), 2019 3.97 [0.49; 31.97]
3.97 [0.49 ; 31.97 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Blood creatinine increased AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Colitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.96 [0.15 ; 59.25 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-130 (all population), 2019 4.95 [0.27; 90.93]
1.97 [0.43 ; 9.07 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
IMpower-130 (all population), 2019 2.96 [0.15; 59.25]
2.40 [0.25 ; 22.76 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-130 (all population), 2019 0.98 [0.33; 2.90]
1.13 [0.41 ; 3.16 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Diabetes mellitus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
IMpower-130 (all population), 2019 0.87 [0.44; 1.70]
0.82 [0.42 ; 1.58 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Dizziness AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dry skin AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.01; 24.77]
0.49 [0.01 ; 24.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-130 (all population), 2019 5.61 [1.31; 24.06]
5.20 [1.39 ; 19.45 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Epistaxis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Fatigue AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
IMpower-130 (all population), 2019 1.28 [0.68; 2.43]
0.76 [0.19 ; 2.97 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 63% 1,254 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86]
IMpower-130 (all population), 2019 0.90 [0.33; 2.46]
0.29 [0.02 ; 4.63 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 72% 1,254 moderate not evaluable Gastritis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Headache AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypertension AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68]
IMpower-130 (all population), 2019 1.48 [0.30; 7.38]
1.00 [0.30 ; 3.31 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Hyperthyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.49 [0.03; 7.86]
0.49 [0.03 ; 7.86 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
1.71 [0.40 ; 7.37 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 29% 1,254 moderate not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
IMpower-130 (all population), 2019 0.73 [0.20; 2.62]
1.49 [0.26 ; 8.74 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 52% 1,254 moderate not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05]
IMpower-130 (all population), 2019 1.57 [0.66; 3.73]
0.79 [0.13 ; 4.82 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 61% 1,254 moderate not evaluable Myalgia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56]
IMpower-130 (all population), 2019 1.59 [0.58; 4.39]
0.67 [0.08 ; 5.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 69% 1,254 moderate not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14]
IMpower-130 (all population), 2019 1.24 [0.88; 1.75]
0.22 [0.01 ; 7.51 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 96% 1,254 moderate not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
IMpower-130 (all population), 2019 0.49 [0.07; 3.49]
0.48 [0.10 ; 2.18 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable Paraesthesia AE (grade 3-4)detailed results IMpower-130 (all population), 2019 1.97 [0.09; 43.77]
1.97 [0.09 ; 43.77 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.73 [0.12; 4.42]
0.73 [0.12 ; 4.42 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.24; 3.96]
0.98 [0.24 ; 3.96 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.71 [0.26; 1.93]
IMpower-130 (all population), 2019 1.40 [0.67; 2.93]
1.09 [0.57 ; 2.07 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 12% 1,254 moderate not evaluable Pneumonitis AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.24 [0.01; 7.31]
0.24 [0.01 ; 7.31 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.98 [0.03 ; 29.35 ] IMpower-130 (all population), 2019 1 0% 705 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-130 (all population), 2019 0.98 [0.03; 29.35]
0.67 [0.06 ; 7.42 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-130 (all population), 2019 2 0% 1,254 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:37 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866